Hospira Vinorelbine Tartrate 50 mg/5 mL Injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Available from:

Hospira Australia Pty Ltd

INN (International Name):

Vinorelbine tartrate

Pharmaceutical form:

Injection

Composition:

Excipient Ingredients: water for injections

Administration route:

Intravenous

Units in package:

1 X 5 mL

Class:

Medicine Listed (Export Only)

Prescription type:

Not scheduled. Not considered by committee

Therapeutic indications:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Vinorelbine is indicated in combination with cisplatin.

Product summary:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2008-05-21